HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nanotech regulation

This article was originally published in The Rose Sheet

Executive Summary

A new report commissioned by the Project on Emerging Nanotechnologies (PEN) at the Woodrow Wilson International Center for Scholars stresses the need for regulatory oversight of nanotechnology and provides a "roadmap" for the Environmental Protection Agency to handle the challenges of the science. In the report, author J. Clarence Davies lays out an agenda designed to create an "effective oversight system" to "minimize any adverse effects of nano-materials," identifying a need for change within the EPA in areas of science, program integration, personnel, international activities and program evaluation, according to a May 23 release. The 76-page report outlines 25 steps that EPA, the government, the U.S. National Nanotechnology Initiative and the nanotechnology industry should take to improve oversight. "This new report seeks to encourage ... an intelligent oversight approach that empowers EPA and promotes investment and innovation in new nanotechnology products and processes," states PEN Director David Rejeski...

You may also be interested in...

Commercialization Phase Brings New Challenges To Nanotech Industry

Increased industry/government collaboration is needed in the field of nanotechnology to move from the research & development phase to the comercialization phase, speakers told the President's Council of Advisors on Science and Technology (PCAST) during a June 25 meeting in Arlington, Va

Health And Wellness Trademark Review 14 January, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts